Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Iovance Biotherapeutics ( (IOVA) ) is now available.
On August 29, 2025, Iovance Biotherapeutics updated its corporate presentation for use at healthcare conferences and with analysts and stockholders. The presentation highlights the company’s progress in TIL therapy, including the commercial launch of products like Amtagvi and Proleukin, and outlines ongoing clinical trials and regulatory submissions, which could impact its market positioning and stakeholder interests.
The most recent analyst rating on (IOVA) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page.
Spark’s Take on IOVA Stock
According to Spark, TipRanks’ AI Analyst, IOVA is a Neutral.
Iovance Biotherapeutics has a weak financial performance due to profitability and cash flow challenges, which significantly impact the overall score. However, the positive earnings call and corporate events provide a more optimistic outlook, suggesting potential for future growth and improved financial health. Technical analysis and valuation indicate mixed signals, with short-term strength but long-term concerns.
To see Spark’s full report on IOVA stock, click here.
More about Iovance Biotherapeutics
Iovance Biotherapeutics, Inc. operates in the biotechnology industry, focusing on the development and commercialization of tumor infiltrating lymphocyte (TIL) therapies for cancer treatment. The company is known for its innovative cell therapy platform aimed at treating solid tumors, with products like Amtagvi and Proleukin, which have received regulatory approvals in the U.S. and Europe.
Average Trading Volume: 17,085,310
Technical Sentiment Signal: Sell
Current Market Cap: $806.9M
Find detailed analytics on IOVA stock on TipRanks’ Stock Analysis page.